Patent ID: 11896722
Assignee: PURDUE PHARMA L.P.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating attention deficit hyperactivity disorder (ADHD) in a subject in need thereof, the method comprising orally administering to the subject a dosage form providing 25, 35, 45, 55, 70, 85, or 100 mg of methylphenidate hydrochloride, wherein the dosage form provides: a first in vivo methylphenidate Tmax and a second in vivo methylphenidate Tmax, wherein in a fed state, the second in vivo methylphenidate Tmax is a Tmax8-16 of about 13.5 hours; and efficacious treatment of ADHD for about 16 hours after a single oral administration, further wherein the dosage form has an in vitro methylphenidate hydrochloride dissolution rate that does not increase in the presence of about either 5% or 20% ethanol when measured under in vitro conditions with stirring at 100 rpm at pH 1.2 for 2 hours in 900 mL of a medium comprising up to about either 5% or 20% v/v ethanol.